December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

3.895 +1.175 (+43.20%)
Streaming Delayed Price Updated: 9:42 AM EDT, Apr 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Recap: Allogene Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Earnings Preview ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation ↗
 
Via Benzinga
Topics ETFs
News headline image
3 Meme Stocks to Sell and Replace With Meme Coins ↗
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs. 
Via InvestorPlace
News headline image
Allogene Therapeutics Announces Q2 Investor Conference Participation
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 ↗
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
Conference Call and Webcast Scheduled for March 14, 2024 at 2:00 p.m. PT/5:00 p.m. ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) rose sharply in today’s pre-market trading. 
Via Benzinga
Topics Stocks
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cell Therapy Focused Allogene Therapeutics' Resource Prioritization A Bold Move, Says Analyst ↗
Allogene Therapeutics Inc (NASDAQ: ALLO) announced deprioritizing the currently enrolling third line Phase 2 ALPHA2 and EXPAND trials of cema-cel (ALLO-501A) and is now pursuing a potentially pivotal... 
Via Benzinga
News headline image
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Applied Therapeutics, Inc. 
Via Benzinga
News headline image
Allogene Layoffs 2024: What to Know About the Latest ALLO Job Cuts ↗
Today, investors in Allogene and ALLO stock aren't cheering a cash burn reduction strategy, with the stock sinking over 15% on the news. 
Via InvestorPlace
Topics Workforce
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking on Friday as we lay out all of the biggest stories worth keeping tabs on this morning! 
Via InvestorPlace
News headline image
Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.; Foresight Diagnostics
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.